# Rachel F. Tyndale

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rachel-f-tyndale/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,969 |
| Field | Smoking Behavior and Cessation |
| h-index | 84 |
| i10-index | 378 |
| Last Known Institution | Centre for Addiction and Mental Health |
| OpenAlex ID | https://openalex.org/A5060841302 |
| ORCID iD | 0000-0003-1297-2053 |
| Works | 585 |

## Researcher papers

- [Guidelines on nicotine dose selection for in vivo research](https://scholariq.org/papers/guidelines-on-nicotine-dose-selection-for-in-vivo-research/)
- [Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes](https://scholariq.org/papers/large-scale-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)
- [Cytochrome P-450 hPCN3, a Novel Cytochrome P-450 IIIA Gene Product That Is Differentially Expressed in Adult Human Liver](https://scholariq.org/papers/cytochrome-p-450-hpcn3-a-novel-cytochrome-p-450-iiia-gene-product-that-is/)
- [A Major Role for CYP2A6 in Nicotine C-Oxidation by Human Liver Microsomes](https://scholariq.org/papers/a-major-role-for-cyp2a6-in-nicotine-c-oxidation-by-human-liver-microsomes/)
- [Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process](https://scholariq.org/papers/incorporation-of-pharmacogenomics-into-routine-clinical-practice-the-clinical/)
- [Nicotine metabolism defect reduces smoking](https://scholariq.org/papers/nicotine-metabolism-defect-reduces-smoking/)
- [Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians](https://scholariq.org/papers/ethnic-variation-in-cyp2a6-and-association-of-genetically-slow-nicotine/)
- [Nicotine without smoke: Tobacco harm reduction](https://scholariq.org/papers/nicotine-without-smoke-tobacco-harm-reduction/)
- [Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial](https://scholariq.org/papers/use-of-the-nicotine-metabolite-ratio-as-a-genetically-informed-biomarker-of/)
- [Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation](https://scholariq.org/papers/nicotine-metabolite-ratio-predicts-efficacy-of-transdermal-nicotine-for-smoking/)

## Researcher topics

- [Smoking Behavior and Cessation](https://scholariq.org/topics/smoking-behavior-and-cessation/)
- [Nicotinic Acetylcholine Receptors Study](https://scholariq.org/topics/nicotinic-acetylcholine-receptors-study/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Neurotransmitter Receptor Influence on Behavior](https://scholariq.org/topics/neurotransmitter-receptor-influence-on-behavior/)
- [Synthesis and Biological Evaluation](https://scholariq.org/topics/synthesis-and-biological-evaluation/)

## Researcher university

- [Centre for Addiction and Mental Health](https://scholariq.org/institutions/centre-for-addiction-and-mental-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.